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A commentary on
Antipsychotic-induced Parkinsonism is associated with working memory deficits in
schizophrenia-spectrum disorders
by Potvin, S., Aubin, G., and Stip, E. (2014). Eur. Arch. Psychiatry Clin. Neurosci. 265, 147–154. doi:
10.1007/s00406-014-0511-y
In a recent study, Potvin et al. (2014) used a multivariate statistical approach to identify
socio-demographic, neurological, drug induced extrapyramidal symptoms (EPS), and psychiatric
predictors of cognitive impairments in patients with a DSM-IV diagnosis of schizophrenia (aged
18–60). Specifically, the study focused on antipsychotic-induced EPS, such as Parkinsonism which
is characterized by hypokinesia, tremors, muscle rigidity, and/or bradykinesia (Tandon and Jibson,
2002). EPS were assessed with the Extrapyramidal Symptoms Rating Scale (ESRS; Chouinard and
Margolese, 2005) and neurocognition was measured using the Cambridge Neuropsychological
Test Automated Battery (CANTAB, Eclipse version 2.0; Elliott et al., 1998). The depressive and
psychiatric symptoms of schizophrenia were evaluated using the Calgary Depression Scale for
Schizophrenia (CDSS; Addington et al., 1992) and the Positive and Negative Syndrome Scale
(PANSS; Kay et al., 1987).
Potvin et al. (2014) found an association between antipsychotic-induced Parkinsonism and
working memory deficits in schizophrenia. Further, it was found that negative symptoms were
associated with increased deficits in cognitive flexibility, working memory, planning, and visual
paired association learning in schizophrenic patients (Elliott et al., 1998). Socio-demographic
variables were also found to be significantly related to cognitive impairment in schizophrenia
patients. These variables included the number of hospitalizations, age, gender, and education level
(Potvin et al., 2014). Prior studies support these findings as it is known that lower SES are correlated
with lower education levels and riskier health behaviors.
It should be noted, however, that while SES was shown by Shah et al. (2012) to be correlated
with cognitive impairments in dementia patients and by Potvin et al. (2014) in schizophrenia
patients, education or income variation alone may not be the reason why low SES is correlated
with cognitive impairments in clinical patients. It could be the differing life choices, occupations
and environments resulting in different levels of propensity across SES groups to experience life
stresses and suffer from chronic or acute illnesses (Schurer et al., 2014). However, it cannot be
discounted that SES factors could simply be comorbid factors with no causal or contributing
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links to cognitive impairments in schizophrenia patients. Further
research is needed to find more definitive causal links or at least
diminish SES factors as confounding variables in understanding
drug induced EPS in schizophrenia patients. These results were
found using multiple hierarchical linear regression analyses
which explored the associations between drug induced EPS and
cognition, while taking into consideration the effect of socio-
demographic and psychopathology variables.
The Potvin et al. (2014) results are in agreement with
previous studies, suggesting a small-to-moderate association
between negative symptoms (but not positive symptoms)
and cognitive impairments in schizophrenia patient. These
cognitive impairments included deficits in problem solving,
attention, reasoning, speed of processing, working memory, and
verbal/visual memory (Ventura et al., 2009).
Potvin et al. (2014) also posited that the number of
hospitalization/duration of illness was found to be associated
with cognitive impairments in schizophrenia patients. These
results are supported by prior studies (Rajji and Mulsant, 2008;
Shah et al., 2012). In the Potvin et al. study, males outperformed
females across the three groups: schizophrenia patients (N =
218), unaffected first degree subjects (N = 438), and healthy
non-relatives volunteers (N = 123), which in agreement to a
cross-sectional study conducted by Torniainen et al. (2011).
Importantly, Potvin et al. (2014) found an association between
antipsychotic-induced Parkinsonism and working memory
deficits in schizophrenia patients. These are consistent with
a study conducted by Jellinger (2010) on Parkinson’s disease
patients with no psychotic disorders, showing moderate working
memory impairments. Further, Potvin et al.’s suggestion of
an association between Parkinsonism and working memory
impairments is supported by the literature. This is likely
related to frontal lobe deficits in first-episode psychosis patients
(Cuesta et al., 2014) and supported by imaging studies
showing abnormal prefrontal dorsolateral cortex activations in
schizophrenia patients while performing memory tasks (Van
Snellenberg et al., 2006). Other studies have also reported a
relationship between motor symptoms (e.g., akinesia or difficulty
moving) and working memory in Parkinson’s disease (Moustafa
et al., 2014).
Potvin et al. (2014) study was naturalistic, that is, participants
were not intentionally recruit based on increased levels of
EPS or for specific symptoms (positive or negative). Rather,
patients were recruited based on their clinical diagnosis,
which makes the association of drug induced Parkinsonism
and memory impairment in schizophrenia patients notable
considering memory deficits are generally considered as an
endophenotype of schizophrenia. While generally speaking
schizophrenia endophenotypes can lead to occupational and
social impairments, cognitive, specifically working memory,
deficits, are one of the leading known causes of impairment in
occupational and social functioning in schizophrenia patients
(Bowie and Harvey, 2005; Barch et al., 2012).
Regardless of SES, prescribing antipsychotics is a common
practice when treating for schizophrenia, even with the well-
documented range of side effects, which include but is
not limited to weight gain, hypotension, sedation, sexual
dysfunctions, emotional instability, and EPS. Further, first-
generation antipsychotics (FGAs), such as chlorpromazine
and haloperidol, are more likely than second-generation
antipsychotics (SGAs), such as Clozapine and Olanzapine,
to produce EPS (Leucht et al., 2013). Additionally, a meta-
analysis conducted by Leucht et al. (2013) on 15 different
antipsychotics (including, Olanzapine, Clozapine, Risperidone,
Chlorpromazine, Zotepine, Asenapine, and Haloperidol) had
shown that different antipsychotics had varying effect sizes
and ranges on patients’ experience of EPS. Importantly, some
studies found that first-generation (typical) antipsychotics,
such as haloperidol, have higher affinity to D2 receptors and
more associated with Parkinsonism than second-generation
(atypical) antipsychotics, such as clozapine (Abi-Dargham and
Laruelle, 2005; Joy et al., 2006; Juckel et al., 2006). It is also
important to note that some studies found that some typical
antipsychotics may similar effects to atypical antipsychotics on
the brain and cognition and that some atypical antipsychotics
are difference from each other, suggesting that the differences
among these drugs can be related to their pharmokinetics,
rather than being typical vs. atypical drug (Kapur et al.,
1999).
As such, the results of Potvin et al. (2014) may be affected
by lacking some experimental control in relation to the dosage
and comparing prescribed antipsychotics. This could be rectified
by calculating and substituting a chlorpromazine equivalent for
participants in this study to rule out any confounding dosage
and drug variations. Further, using unaffected relatives and
healthy control group for comparative data of performance could
have provided further insight on drug induced Parkinsonism in
schizophrenia patients.
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